These regulatory wins (especially the second) are lifting Vertex's stock, a rally that could continue for much of the year. Alyftrek should start making some noise, as will Journavx. Vertex's Casgevy, a gene-editing treatment for two rare blood-related diseases that has been on the market for a little over a year, could also contribute to the company's financial results.